Evidence map›Paper›PMID 36031501›Full record

Observational studyVaccine2022

Safety, immunogenicity, and immune persistence of two inactivated COVID-19 vaccines replacement vaccination in China: An observational cohort study.

Xiaoqi Wang, Yao Deng, Li Zhao, Lei Wang, Zhenwang Fu, Lin Tang, Fei Ye, Qianqian Liu, Wenling Wang, Siquan Wang and 9 more

Open access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Vaccine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 1 country.

Xiaoqi WangNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Yao DengNHC Key Laboratory of Biosafety, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Li ZhaoNHC Key Laboratory of Biosafety, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Lei WangHubei Provincial Center for Disease Control and Prevention, Wuhan, China.
Zhenwang FuHainan Provincial Center for Disease Control and Prevention, China.
Lin TangNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Fei YeNHC Key Laboratory of Biosafety, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Qianqian LiuNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Wenling WangNHC Key Laboratory of Biosafety, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Siquan WangHubei Provincial Center for Disease Control and Prevention, Wuhan, China.
Bo HuDanzhou Center for Disease Control and Prevention, China.
Xuhua GuanHubei Provincial Center for Disease Control and Prevention, Wuhan, China.
Zhuling HanWenchang Center for Disease Control and Prevention, China.
Yeqing TongHubei Provincial Center for Disease Control and Prevention, Wuhan, China.
Lance E RodewaldNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Zundong YinNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Wenjie TanNHC Key Laboratory of Biosafety, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Fuzhen WangNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China. Electronic address: wangfz@chinacdc.cn.
Baoying HuangNHC Key Laboratory of Biosafety, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China. Electronic address: huangby@ivdc.chinacdc.cn.
Chinese Center For Disease Control and Prevention · CNNational Institute for Viral Disease Control and Prevention · CNHubei Provincial Center for Disease Control and Prevention · CNHainan Center for Disease Control & Prevention · CNNanchang Center for Disease Control and Prevention · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo mitigate a national shortage of WIBP-CorV COVID-19 vaccine, China's regulator approved administering BBIBP-CorV after WIBP-CorV for completion of a primary series. In a pragmatic observational study, we compared immunogenicity and safety of a primary series of WIBP-CorV followed by BBIBP-CorV with a primary series of two doses of BBIBP-CorV.

methodsWe invited healthy 18-59-years-old adults who had already received either WIBP-CorV or BBIBP-CorV as their first dose in a primary series to participate in this observational cohort study. Subjects who had received WIBP-CorV as their first dose became the observation group; subjects who had received BBIBP-CorV as their first dose became the control group. All participants received BBIBP-CorV as their second dose. We obtained sera 1, 2, and 6 months after second doses for nAb titer measurement by micro-neutralization cytopathic effect assay with SARS-CoV-2 strain HB01, standardized with WHO International Standard for anti-SARS-CoV-2 immunoglobulin. Safety was assessed for the 7 days after administration of second doses.

resultsBetween March and December 2021, 275 subjects were included in the observation group and 133 in the control group. Neutralizing seropositivity (≥1:4) rates were 98.91 % and 99.25 % at 1 month and 53.16 % and 70.69 % at 6 months. One-month geometric mean titers (GMTs) were 21.33 and 22.45; one-month geometric mean concentrations (GMCs) were 227.71 IU/mL and 273.27 IU/mL. One to two months after vaccination, observation group seropositivity rates and titers were not significantly different to the control group's. Adverse reaction rates were 11.27 % and 18.80 %, all mild or moderate in severity.

conclusionsBoth primary series were immunogenic; immunogenicity of WIBP-CorV followed by BBIBP-CorV was not different than immunogenicity following two doses of BBIBP-CorV for two months after vaccination; safety profiles were acceptable for both regimens. BBIBP-CorV can be used to complete a primary series that started with WIBP-CorV.

Indexed as

COVID-19COVID-19 VaccinesAdolescentAdultAntibodies, ViralCohort StudiesHumansImmunogenicity, VaccineMiddle AgedSARS-CoV-2VaccinationVaccines, InactivatedYoung AdultAntibodies, ViralCOVID-19 VaccinesVaccines, InactivatedCOVID-19Immune persistenceImmunogenicityInactivated vaccineReplacement vaccineSafety

Identifiers

PMID36031501
PMCPMC9393163
OpenAlexW4292553227

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.